CNC slides over 3% as technical setup and Medicaid uncertainty drive selling pressure

Traders Union
All News
Financial News
Centene slides 3.14% to $63.82 today

Highlights

Centene maintains its 2024 outlook with projected annual revenue exceeding $100 billion, emphasizing profitability gains and cost controls.
Investors focus on ongoing challenges from Medicaid redeterminations, membership declines, and pressure on revenue streams ahead of Q2 2026 results.
Despite intraday weakness, technicals indicate medium- and long-term bullish momentum, with a trading range expected between $61.24 and $65.81 over the next week.

Investor focus sharpens on profitability amid persistent Medicaid-driven pressures

Centene is scheduled to report its second-quarter 2026 earnings on July 28, 2026, with ongoing focus from investors on profitability improvements and ongoing challenges related to membership declines and revenue pressures driven by Medicaid redeterminations. The company recently reiterated its 2024 financial guidance, including a projection of total annual revenue above $100 billion and an increased outlook for adjusted diluted earnings per share, following progress in cost management and a more profitable business mix. Adjustments to institutional holdings by Bank of New York Mellon and other community health initiatives were also reported, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes Centene's 3.14% drop highlights persistent vulnerability to membership declines and ongoing Medicaid redetermination pressures. He sees technical signals as mixed — intraday seller pressure dominates, but the longer-term uptrend is not yet invalidated. Kharitonov points out that institutional adjustments and reiterated guidance have failed to shift cautious market sentiment. Divergence among momentum indicators suggests the setup favors only limited upside until new demand emerges. "Given the continued resistance and lackluster response to improved guidance, I see any recovery attempts as likely short-lived unless underlying membership metrics show clear improvement," Kharitonov says.

Viktoras Karapetjanc, expert at Traders Union, sees continued optimism for Centene as the company stands by improved earnings guidance and robust revenue forecasts above $100 billion. He emphasizes the ongoing business mix improvements and institutional engagement as signs of underlying strength. Karapetjanc believes the long-term bullish structure remains intact, supported by the alignment of key moving averages. He expects upward potential, especially if short-term resistance at $64.52 is breached in coming sessions. "With strong fundamentals and improving profitability, I remain confident in Centene’s ability to deliver further growth for patient investors," says Karapetjanc.

Long-term bullish signals contrast with short-term downside and indicator divergence

Centene is trading below its 20-day moving average ($66.29), above its 50-day moving average ($62.99), and well above its 200-day moving average ($45.71), indicating near-term seller pressure with continued support for the medium- and long-term uptrend. Immediate resistance is seen at $64.52 and support at $63.65, with a bullish long-term structure reflected in the alignment of the 50-day and 200-day moving averages. Momentum indicators show strong upward movement as the MACD and ADX both signal strength, while the RSI at 52.42 gives a buy forecast. The Stochastic RSI at 25.09, however, gives a sell indication, highlighting divergence between short- and long-term oscillators. The CCI is neutral, and Bull/Bear Power at 1.14 points to intraday buyer dominance and an overbought reading. Intraday volatility stands at 1.61%, with the stock trading near session lows as downside pressure followed an opening gap.

Earlier, analysts noted that Centene’s improved earnings outlook and board expertise had underpinned a constructive long-term view despite sector shifts. The current setup adds a layer of caution due to ongoing selling pressure and Medicaid-related headwinds, making a confirmed breakout above $64.52 the key signal for renewed upside momentum.

Source of Data: CNC Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.